INT165132

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 6
Disease Relevance 1.15
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nuclear envelope (Ptgs1) aging (Ptgs1) Golgi apparatus (Ptgs1)
endoplasmic reticulum (Ptgs1) cytoplasm (Ptgs1) lipid binding (Ptgs1)
Ptgs1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
c fibre 6 50.00 Quite Low
Inflammation 6 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 6 97.68 Very High Very High Very High
Overactive Bladder 18 95.92 Very High Very High Very High
Pollakiuria 6 5.00 Very Low Very Low Very Low
INFLAMMATION 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Localization (administration) of cyclooxygenase-1
1) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (underwent) of Localization (administration) of cyclooxygenase
2) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Localization (administration) of cyclooxygenase-1
3) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Localization (administration) of cyclooxygenase
4) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (underwent) of Localization (administration) of cyclooxygenase-1
5) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Negative_regulation (inhibitor) of Localization (administration) of cyclooxygenase
6) Confidence 0.42 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox